Skip to content

    Uflex

    UFLEXGood
    Capital Goods·20 May 2025
    Management Summary

    Uflex reported a strong turnaround in FY25, with significant revenue and EBITDA growth, and a return to PAT positive. This performance was driven by improved Packaging Films volumes and margins, and robust utilization in Aseptic Packaging. The company is focused on ramping up new capacities, managing debt, and optimizing operations, with a positive outlook for FY26 despite potential BOPP capacity overhang.

    Highlights

    8
    • Consolidated revenue for FY25 increased by 12.4% to over ₹15,000 crores.

    • Operational EBITDA for FY25 grew by approximately 18% compared to FY24.

    • The company reported a PAT positive of approximately ₹142 crores in FY25, a significant turnaround from a loss of ₹690 crores in FY24.

    • Packaging Films business saw a volume increase of 10.4% and sales growth of 10.3% in FY25.

    • Aseptic Packaging achieved over 110% capacity utilization, producing 7.87 billion packs against a 7 billion pack capacity in FY25.

    • Gross debt stood at approximately ₹8,100 crores and net debt at ₹6,800 crores as of March 31, 2025.

    • Total capex for FY25 was ₹1,726 crores, with a planned capex of ₹1,200 crores for FY26.

    • Guidance for FY26 includes 10% revenue growth and an EBITDA of approximately ₹2,100 crores.

    Key financials

    Metrics

    8

    Periods

    2

    Headline

    6
    • Consolidated Revenue
      ₹15,000 Cr
      YoY+12.4%
    • Operational EBITDA Growth
      18%
      YoY+18%
    • PAT
      ₹142 Cr
    • Exceptional Loss
      ₹177 Cr
    • Gross Debt
      ₹8,100 Cr

    FY25

    2
    • Capex
      ₹1,726 Cr
    • Debt-to-EBITDA
      3.6 ratio

    Segment breakdown

    Packaging Films
    10.4% Volume Growth (FY25)10.3% Sales Growth (FY25)77.7% Contribution to Business
    Aseptic Packaging
    7.87 billion packs Volume (FY25)110% Capacity Utilization (FY25)
    List

    Guidance & targets

    13
    CategoryTargetPriority
    Capacity
    Aseptic Packaging Capacity
    12 billion packs
    High
    Capacity
    BOPP Capacity Addition (India)
    20,000 tons
    High
    Debt
    Long-term Debt Repayment
    ₹1,175 crores
    High
    Debt
    Debt-to-EBITDA Ratio
    3.9
    Medium
    Capex
    Ongoing Expansion Projects Capex
    ₹1,200 crores
    High
    Capex
    Recycling Investment (Noida)
    ₹317 crores
    High
    Volume
    Aseptic Packaging Volumes
    10 billion to 10.5 billion packs
    Medium
    Revenue
    Revenue Growth
    10%
    High
    Revenue
    Mexico PET Film Packaging Plant Turnover
    $50 million
    High
    Profitability
    EBITDA Margin
    12.5% to 13%
    High
    Profitability
    EBITDA
    ₹2,100 crores
    High
    Margin
    Packaging Film Industry Margins
    10% to 11%
    Medium
    Margin
    Pet Food Packaging Business EBITDA Margin
    22% to 24%
    High

    Risks & concerns

    7
    RiskSeverity

    BOPP capacity expansions and potential impact on pricing and margins

    Industry-wide BOPP capacity expansions are expected from June onwards, which could impact pricing and margins, requiring close monitoring.Management acknowledged

    medium

    Increased competition in Aseptic Packaging from new players

    Analysts raised concerns about new players like SIG and GLS Elopak commissioning plants, but management expressed confidence due to market growth and technological differences.Analyst downplayed

    medium

    Volatility in BOPET and BOPP prices

    Significant price volatility in BOPET and BOPP in the domestic market was noted, but management stated it leads to inter-segment adjustments without major financial deviations.Analyst acknowledged

    medium

    Impact of Indian capacity overhang on European plants

    Indian capacity overhang has led to cheaper imports into Europe, affecting capacity utilization at Uflex's Poland facility.Management acknowledged

    medium

    Stabilization time and initial profitability for new projects

    Management noted that new projects take time to stabilize, and initial profitability might not meet full expectations for the first couple of years.Management acknowledged

    low

    Areas of Evasion(2)

    • exact BOPET/BOPP spreads for Q4
    • specific FY27 guidance

    Q&A highlights

    3

    “No, we are not doing the chemical recycling. We are only doing the mechanical recycling. So mechanical recycling, the recycled material ultimately is going to be a bit more expensive for the buyers... But on the whole, even after everything that does settle and the normalcy comes, still it will be expensive as compared to virgin.”

    Clarifies Uflex's recycling strategy (mechanical only) and its cost implications compared to virgin materials, which is crucial for understanding their sustainability investments.

    asked by Shashank Agarwal

    2 min read6 chapters

    Detailed Narrative

    01

    FY25 Financial Performance and Turnaround

    Uflex reported a strong financial turnaround in FY25, with consolidated revenue increasing by 12.4% to over ₹15,000 crores. Operational EBITDA saw a substantial 18% growth compared to FY24. Notably, the company achieved a PAT positive of approximately ₹142 crores, a significant recovery from a loss of ₹690 crores in the previous fiscal year. This improvement was supported by a reduction in exceptional losses to ₹177 crores in FY25 from ₹871 crores in FY24.

    02

    Packaging Films and Aseptic Business Highlights

    The Packaging Films business was a key driver, with volumes growing by 10.4% and sales by 10.3% in FY25, surpassing 500,000 tons in production and sales for the first time. Margins in this segment also improved. The Aseptic Packaging business continued its strong performance, producing 7.87 billion packs against a 7 billion pack capacity, achieving over 110% utilization. The company expects to commission its 12 billion packs capacity soon, aiming for 10-10.5 billion packs volume in FY26.

    03

    Debt Management and Capex Plans

    As of March 31, 2025, Uflex's gross debt stood at approximately ₹8,100 crores, with net debt at ₹6,800 crores, and cash reserves of ₹1,273 crores. The company spent ₹1,726 crores on capex in FY25 and plans to spend around ₹1,200 crores in FY26 for ongoing expansion projects. Management aims to repay approximately ₹1,175 crores of long-term debt in FY26, while acknowledging that new debt might be added for working capital needs related to business growth.

    04

    FY26 Outlook and Margin Expectations

    For FY26, Uflex projects a 10% revenue growth, translating to approximately ₹16,700 crores. The EBITDA margin is expected to be in the range of 12.5% to 13%, leading to an estimated EBITDA of ₹2,100 crores. The debt-to-EBITDA ratio is projected to be around 3.9 in FY26/FY27. Packaging film industry margins are expected to remain in the 10% to 11% range.

    05

    Recycling and Sustainability Initiatives

    Uflex is investing significantly in mechanical recycling, with a ₹317 crore project underway in Noida. Management clarified that mechanical recycling, while more expensive than virgin PET, is a proven method and their recycled products are US FDA approved for food packaging. They anticipate increased demand for films made from recycled PET bottles and expect sustainability initiatives to perform better in FY26.

    06

    International Operations and Capacity Utilization

    The company highlighted efforts to optimize capacity utilization in international plants, particularly in Nigeria and Poland, which have faced pressure from cheaper imports. The Mexico PET film packaging plant is expected to achieve a turnover of $50 million (approx. ₹450 crores) at full capacity, with the pet food packaging business targeting an EBITDA margin of 22-24%. The Aseptic Packaging expansion in Egypt, with a 12 billion pack capacity, is expected to support both international and domestic demand, allowing for strategic export shifts.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.